scholarly journals Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis

Aging ◽  
2019 ◽  
Vol 11 (24) ◽  
pp. 12568-12580
Author(s):  
Changjiang Lei ◽  
Xiulan Peng ◽  
Xiaojun Gong ◽  
Ying Fan ◽  
Shenglin Wu ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Meta Analysis ◽  
Prognostic Role ◽  
Programmed Death Ligand 1 ◽  
Tract Cancer ◽  
Programmed Death

The prognostic role of soluble transforming growth factor-β (sTGFb) and soluble programmed death-ligand 1 (sPDL1) in biliary tract cancer patients treated with binimetinib and capecitabine.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 257-257
Author(s):  
Jin Won Kim ◽  
Kyung-Hun Lee ◽  
Ji-Won Kim ◽  
Koung Jin Suh ◽  
Ah-Rong Nam ◽  
...  
Keyword(s):  
Growth Factor ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Transforming Growth Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Prognostic Role ◽  
Programmed Death Ligand 1 ◽  
Positive Correlation ◽  
Tract Cancer ◽  
Programmed Death

257 Background: Transforming growth factor (TGF) -β signaling is important for tumor growth and metastasis in biliary tract cancer (BTC). TGF-β attenuates tumor response to programmed death-ligand 1 (PD-L1) blockade. This study aimed to evaluate a correlation between soluble TGF-β (s TGF-β) and soluble PD-L1 (sPD-L1) and its prognostic role in BTC. Methods: Study population consisted of 34 patients enrolled in phase Ib clinical trial of binimetinib (MEK inhibitor) with capecitabine in gemcitabine-pretreated BTC (ClinicalTrials.gov: NCT02773459). Blood samples at screening, after first cycle, after second cycle, and at disease progression were prospectively collected. Plasma sTGF-β and sPD-L1 values were measured by using an enzyme-linked immunosorbent assay. Results: In total 34 patients, 25 (73.5%) and 9 patients (26.5%) were second-line and third-line setting, respectively. Median progression-free survival (PFS) and overall survival (OS) were 4.1 and 7.8 months. The mean baseline sTGF-β and sPD-L1 were 18.7 ng/ml and 3.1 ng/ml. There was a positive correlation between sTGF-β and sPD-L1 value (pearson correlation = 0.596, p < 0.001). Mean baseline value was likely to be higher in best response of progressive disease, followed by stable disease and partial response. Similarly, higher baseline sTGF-β showed significantly shorter PFS (3.4 vs 5.1 months (m), p = 0.047) and OS (5.4 vs 9.7 m, p = 0.042). Higher baseline sPD-L1 also had a trend for poor PFS and OS (PFS: 3.0 vs 4.3 m, p = 0.220; OS: 6.4 vs 9.7 m, p = 0.140). Regarding changes from baseline to after first cycle, sTGF-β change of > 3.6 ng/ml demonstrated significantly shorter OS (5.9 vs 10.8 m, p = 0.020), although PFS did not differ according to sTGF-β change (p = 0.210). In contrast, OS did not differ according to sPD-L1 change (p = 0.190). sPD-L1 change > -1.7 ng/ml even had longer PFS (5.1 vs 2.2 m, p = 0.005). Conclusions: In BTC patients with binimetinib and capecitabine, there is a positive correlation between sTGF-β and sPD-L1 value and higher baseline sTGF-β and sPD-L1 indicate a worse prognosis. The early change of sTGF-β and sPD-L1 during treatment could predict the survival.

Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis

2016 ◽  
Vol 11 (6) ◽  
pp. 753-761 ◽  
Author(s):  
Xue Li ◽  
Minghuan Li ◽  
Zhen Lian ◽  
Hui Zhu ◽  
Li Kong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Prognostic Role ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index

2021 ◽  
Author(s):  
Giulia Rovesti ◽  
Francesco Leone ◽  
Giovanni Brandi ◽  
Lorenzo Fornaro ◽  
Mario Scartozzi ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Prognostic Role ◽  
Tract Cancer

Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer

2017 ◽  
Vol 42 (3) ◽  
pp. 823-834 ◽  
Author(s):  
Ka Wing Ma ◽  
Tan To Cheung ◽  
Wong Hoi She ◽  
Kenneth Siu Ho Chok ◽  
Albert Chi Yan Chan ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Fdg Pet ◽  
Prognostic Role ◽  
Tract Cancer ◽  
Pet Ct ◽  
Fdg Pet Ct

Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer

Oncology ◽  
2021 ◽  
pp. 1-8
Author(s):  
Hyera Kim ◽  
Jinchul Kim ◽  
Seonggyu Byeon ◽  
Kee-Taek Jang ◽  
Jung Yong Hong ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Checkpoint Inhibitors ◽  
Progression Free Survival ◽  
Tumor Location ◽  
Extrahepatic Cholangiocarcinoma ◽  
Programmed Death Ligand 1 ◽  
Tract Cancer ◽  
Programmed Death ◽  
Combined Positive Score

Background: Biliary tract cancer (BTC) is associated with poor prognosis because of its aggressive and heterogeneous nature. Programmed death ligand 1 (PD-L1) has been considered a novel biomarker for prognosis and response of immune checkpoint inhibitors in various tumors. However, there are limited data reporting on the role of PD-L1 in advanced BTC patients. Patients and Methods: We analyzed 186 patients with advanced BTC who received palliative gemcitabine and platinum between May 2010 and December 2019. All patients were evaluated for PD-L1 expression by combined positive score positivity. Results: Of the 186 patients, the primary tumor location was intrahepatic cholangiocarcinoma (IHCC) in 72 (38.7%), extrahepatic cholangiocarcinoma (EHCC) in 90 (48.4%), and gallbladder (GB) cancer in 24 (12.9%). Among all the patients, 53 (28.5%) had PD-L1 positivity. The median overall survival (OS) of patients with PD-L1 positivity or negativity was 12.1 and 15.4 months, respectively. The median progression-free survival (PFS) in patients with PD-L1 positivity or negativity was 5.7 and 7.1 months, respectively. OS and PFS were not statistically different between groups. In subgroup analysis, EHCC patients with PD-L1 negativity had more favorable OS (17.2 vs. 11.6 months, p = 0.002) and PFS (7.8 vs. 5.4 months, p = 0.005) than those who were PD-L1-positive. However, this finding was not reproduced in patients with IHCC or GB cancer. Conclusion: This study demonstrated that PD-L1 expression might be a novel prognostic biomarker in patients with EHCC but not in patients with IHCC or GB cancer.

Sign in / Sign up

Export Citation Format

Share Document